| Acquisitions | Country | Date of acquisition | Net sales, SEKm¹ | Number of employees¹ | Business area |
|---|---|---|---|---|---|
| MBA Incorporado S.L | Spain | January, 2022 | 670 | 285 | Medtech |
| Business from Telia Health Monitoring | Sweden | March, 2022 | 4 | 8 | Medtech |
| O'Flynn Medical Ltd | Ireland | April, 2022 | 64 | 36 | Medtech |
| BioCat GmbH | Germany | April, 2022 | 90 | 20 | Labtech |
| JK Lab Nordic AB | Sweden | July, 2022 | 24 | 6 | Labtech |
| Emmat Medical Ltd | Great Britain | September, 2023 | 28 | 4 | Medtech |
| ¹ Refers to conditions at the time of acquisition on a full-year basis. | |||||
| According to the acquisition analyses, the acquisitions carried out during financial year 2023 were as follows: | |||
|---|---|---|---|
| Fair value | |||
| Intangible non-current assets | 4 | ||
| Other non-current assets | 1 | ||
| Inventories | 1 | ||
| Other current assets | 3 | ||
| Deferred tax liability/tax asset | -1 | ||
| Other liabilities | -3 | ||
| Acquired net assets | 5 | ||
| Goodwill | 7 | ||
| Consideration¹ | 12 | ||
| Less: cash and cash equivalents in acquired businesses | -1 | ||
| Contingent consideration not yet paid | -5 | ||
| Effect on the Group’s cash and cash equivalents | 6 | ||
| ¹ The consideration is stated excluding acquisition expenses. | |||
| According to the acquisition analyses, the acquisitions carried out during financial year 2022 were as follows: | |||
| Fair value | |||
| Intangible non-current assets | 582 | ||
| Other non-current assets | 428 | ||
| Inventories | 274 | ||
| Other current assets | 457 | ||
| Deferred tax liability/tax asset | -133 | ||
| Other liabilities | -1,024 | ||
| Acquired net assets | 584 | ||
| Goodwill | 412 | ||
| Consideration¹ | 996 | ||
| Less: cash and cash equivalents in acquired businesses | -200 | ||
| Contingent consideration not yet paid | -21 | ||
| Effect on the Group’s cash and cash equivalents | 775 | ||
| ¹ The consideration is stated excluding acquisition expenses. | |||
All acquisition analyses were determined. The unspecified amounts refer to assets and equity and are not significant.
The purchase price for this year's acquisition amounts to SEK 12 million (996), whereof SEK 7 million (412) was allocated to goodwill and SEK 4 million (582) to other intangible assets. The consideration consists of cash payment. The transaction costs for the acquisitions with a takeover date during the 2023 financial year totalled SEK 0 million (12) and are recognised in selling expenses.
The outcome of additional contingent considerations depends on the results achieved in the companies and has a set maximum level. The fair value of not yet paid contingent consideration for acquisitions made during the financial year is calculated to SEK 5 million, which is approximately 100 percent of the maximum outcome. Previously completed acquisitions where the purchase price has not yet been paid, the estimated fair value amounts to SEK 86 million, which constitutes approximately 87 percent of the maximum outcome.
The values allocated to intangible assets, such as supplier relationships, were assessed at the discounted value of future cash flows. The amortisation period is determined by estimating the annual decrease in sales attributable to each asset.
Supplier relationships are generally amortised over a period of 10 years. The goodwill that arose in connection with the acquisitions is due to the fact that the Group's position in the current market for each acquisition is expected to be strengthened and to the knowledge gained in the acquired companies.
The goodwill resulting from the acquisitions is attributable to expectations that the Group's position in the market in question for each acquisition will grow stronger and to the knowledge accumulated in the companies acquired.
The effect of the acquisition, on consolidated net sales was SEK 8 million (952), while the effect on EBITA was SEK 1 million (162), operating profit was SEK 1 million (114) and after-tax profit for the year was SEK 0 million (62). Had the acquisition, been completed on 1 January 2023, the impact would have been approximately SEK 11 million (1,011) on consolidated net sales, SEK 1 million (174) on EBITA, about SEK 1 million (122) on operating profit, and about SEK 1 million (68) on profit after-tax.
Additional purchase fees of SEK 16 million have been paid during the financial year regarding Ropox, which was acquired in 2020.